Immix Biopharma announces 89% complete response rate across Nexicart-2 patients
IMMX•Immix Biopharma reported an 89% complete response rate across Nexicart-2 patients, with MRD-negativity indicating potential for a rate of up to 98%; all new patients were in complete response or MRD-negative.
1. Interim trial update
Immix Biopharma said all new Nexicart-2 patients were in complete response or MRD-negative. The company plans a final readout and BLA submission for mid-2027.
